Addex Therapeutics (ADXN) Cash from Investing Activities (2019 - 2024)

Addex Therapeutics has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$5322.2 billion for Q4 2024.

• Cash from Investing Activities for Q4 2024 came in at -$5322.2 billion, down 83849.9% year-over-year; the trailing twelve-month figure through Dec 2024 was -$5321.9 billion (down 7390439.96% YoY), and the FY2025 annual result was -$820996.0, down 115.48% from the prior year.
• Cash from Investing Activities came in at -$5322.2 billion for Q4 2024 at Addex Therapeutics, down from -$5.3 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $6.4 billion in Q4 2023 to a low of -$5322.2 billion in Q4 2024.
• The 5-year median for Cash from Investing Activities is -$3494.0 (2021), against an average of -$355.2 billion.
• Across the five-year window, Cash from Investing Activities soared 68023499414.92% in 2023 and slumped 83849.9% in 2024, its largest moves.
• Addex Therapeutics' Cash from Investing Activities stood at -$53189.5 in 2020, then jumped by 50.25% to -$26460.8 in 2021, then soared by 99.96% to -$9.34 in 2022, then jumped by 68023499414.92% to $6.4 billion in 2023, then plunged by 83849.9% to -$5322.2 billion in 2024.
• The last three Cash from Investing Activities figures came in at -$5322.2 billion (Q4 2024), -$5.3 billion (Q3 2024), and $6.4 billion (Q4 2023), per Business Quant data.